Tilray Earnings Call Highlights Growth Amid Margin Pressures

Tilray ((TLRY)) has held its Q3 earnings call. Read on for the main highlights of the call.

Tilray’s latest earnings call struck a cautiously upbeat tone, as management highlighted record quarterly revenue, stronger international cannabis sales, and meaningful cost savings while acknowledging pressure in its beverage unit and ongoing regulatory risks. Executives emphasized that operational gains, improved liquidity, and strategic deals are starting to outweigh the near-term headwinds facing the business.

Record Revenue Underscores Organic Growth Momentum

Tilray posted third-quarter net revenue of $206.7 million, an 11% year-over-year increase and the highest Q3 in its history, which management described as organic growth. The performance signals that core demand across the portfolio is expanding despite price pressure in some markets and softer beverage trends.

Profitability Metrics Improve with Higher Adjusted EBITDA

Gross profit rose 6% year over year to $55 million, with margins edging down slightly to 27% from 28% as mix and input costs weighed on profitability. Adjusted EBITDA climbed 19% to $10.7 million, and executives reiterated their confidence in reaching $62 million to $72 million of adjusted EBITDA in fiscal 2026.

International Cannabis Delivers Surging Volumes

International cannabis net sales jumped 73% from a year earlier to $24.1 million, rising 20% sequentially on what management called exceptional volume growth. Medical cannabis flower volumes doubled and oil volumes rose 90%, with Germany standing out at 43% year-over-year growth for the quarter.

Tilray Pharma Distribution Extends European Reach

Distribution revenue through Tilray Pharma hit $83 million, up 35% year over year and marking the strongest third quarter on record for the segment. With CC Pharma recognized as a top European innovator and new deals expanding German pharmacy coverage from 13,000 to 16,000 locations plus fresh UK access via Smartway, the company sees distribution as a key growth engine.

BrewDog Deal and Carlsberg Pact Build Beverage Scale

Tilray acquired BrewDog assets for about EUR 40 million, projecting that the transaction will add roughly $225 million to $250 million in revenue and help create a near $500 million global craft beverage platform on a pro forma basis. Management also flagged a U.S. licensing partnership beginning in 2027 with Carlsberg that will allow Tilray to produce, market, and distribute Carlsberg brands domestically, supporting a pro forma company run-rate around $1.2 billion.

Liquidity Improves with Net Cash Position

The company ended the quarter with $264.8 million in cash, restricted cash, and marketable securities, moving into a net cash position of about $3.5 million versus net debt a year ago. That shift represents an improvement of roughly $40.2 million and gives Tilray more flexibility to navigate volatility and integrate recent acquisitions.

Project 420 Delivers Targeted Cost Savings

Management reported the completion of Project 420 and the realization of its $33 million annualized cost-savings goal, aimed at resetting the beverage cost base and supporting margins. During the quarter alone, Tilray captured more than $6.2 million of annualized savings, which executives say should increasingly flow through to profitability as integration work continues.

Wellness Segment Grows with Better Margins

Wellness revenue climbed 16% year over year to $16.4 million, supported by new value-added products and targeted pricing initiatives. Segment gross margin edged up to 33% from 32%, suggesting that innovation and disciplined pricing are helping offset broader cost pressures.

Beverage Segment Faces Revenue and Margin Strain

Beverage net revenue declined to $42.6 million from $55.9 million in the prior-year quarter, reflecting distribution changes and category softness. Gross margin in the segment compressed to 32% from 36% due to lower production leverage and higher input costs, and management acknowledged that the beverage portfolio remains a work in progress despite early benefits from Project 420.

Commodity Cost Volatility Adds Margin Headwinds

Higher prices for aluminum, fuel, and hops continued to weigh on results, with aluminum alone adding almost $2.9 million in extra costs year to date. Tilray is hedging 65% to 75% of monthly aluminum purchases and extending coverage a year out, but executives cautioned that volatile input prices will remain a drag on margins.

Price Compression Erodes International Cannabis Revenue

While volumes surged in international cannabis, Tilray noted that price compression shaved roughly $7 million from revenue in the segment. The margin pressure partly offset the benefits of higher sales and underscores the competitive dynamics facing cannabis suppliers in key markets such as Europe.

Working Capital Build Weighs on Operating Cash Flow

Cash used in operations widened to $21.9 million from $5.8 million a year earlier, driven largely by inventory buildup ahead of a seasonally stronger fourth quarter and higher receivables tied to international growth. Excluding working capital, the business generated $3.4 million of operating cash, suggesting underlying operations are improving even as growth investments consume cash.

Regulatory Uncertainty Clouds U.S. Hemp and Cannabis

Management highlighted ongoing uncertainty around U.S. rescheduling efforts, potential pilot programs, and possible changes to hemp-derived THC rules that could curb products above certain thresholds. These moving pieces create risk for Tilray’s U.S. hemp-based beverage business and could reshape the opportunity set in that market over the next few years.

Integration Tasks Create Near-Term Operational Noise

The BrewDog acquisition, completed out of administration, requires substantial stabilization work, including catching up on supplier payments, rehiring and staffing, and restarting plant operations. Alongside SKU, plant, and distributor rationalizations and the timing of spring shelf resets, these efforts have caused temporary distribution losses and contributed to uneven beverage performance.

Net Loss Narrows Sharply but Profit Still Elusive

Tilray reported a net loss of $25.2 million for the quarter, a sharp improvement of $768.3 million from the prior year when results were weighed down by a large noncash impairment. Despite the progress, the company remains loss-making on a GAAP basis, leaving a clear profitability gap that management aims to close through growth, cost savings, and mix shifts.

Guidance Anchored by Cost Savings and Scale Gains

Looking ahead, Tilray reaffirmed its fiscal 2026 adjusted EBITDA target of $62 million to $72 million, pointing to record Q3 revenue, a 19% rise in adjusted EBITDA, and ongoing cost efficiencies as key supports. Management stressed that the completed $33 million cost-savings program, improving beverage margins near 32%, a diversified revenue mix across cannabis, distribution, beverage, and wellness, and active commodity hedging all underpin their confidence despite working capital drag and lingering market volatility.

Tilray’s earnings call painted the picture of a company gaining scale and operational discipline while still wrestling with margin pressure, integration complexities, and regulatory unknowns. For investors, the story hinges on whether rising international cannabis demand, an expanding beverage platform, and realized cost savings can ultimately translate into sustainable profitability and stronger cash generation.